OpenURL Connection Search

Select item for more details and to access through your institution.

Patient socioeconomic status as a prognostic factor for allo-SCT.
Published in:
Bone Marrow Transplantation, 2009, v. 43, n. 7, p. 571, doi. 10.1038/bmt.2008.358
By:
- Silla, L.;
- Fischer, G. B.;
- Paz, A.;
- Daudt, L. E.;
- Mitto, I.;
- Katz, B.;
- da Graça Grossini, M.;
- Bittencourt, H. N.;
- Jochims, A.;
- Fogliatto, L.;
- Bittar, C. M.;
- Friedrisch, J. R.;
- Bittencourt, R. I.
Publication type:
Article
Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase.
Published in:
Bone Marrow Transplantation, 2008, v. 42, n. 9, p. 597, doi. 10.1038/bmt.2008.218
By:
- Bittencourt, H;
- Funke, V;
- Fogliatto, L;
- Magalhães, S;
- Setubal, D;
- Paz, A;
- Macedo, A V;
- Ruiz, J;
- Azambuja, A P;
- Silla, L;
- Clementino, N;
- Pasquini, R
Publication type:
Article
SUNMO: PHASE III TRIAL OF MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN IN RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMA.
Published in:
Hematological Oncology, 2023, v. 41, p. 170, doi. 10.1002/hon.3163_T05
By:
- Pavlovsky, A.;
- Westin, J.;
- Olszewski, A. J;
- Fogliatto, L.;
- Kim, W. S.;
- Shin, H.;
- Leão, D.;
- Jeon, Y.;
- Norasetthada, L.;
- Rego, E.;
- Wu, H.;
- Yin, S.;
- Batlevi, C. L.;
- Pham, S.;
- Penuel, E.;
- Jing, J.;
- Wei, M. C.;
- Budde, L. E.
Publication type:
Article
Cause of death and prognosis of patients (pts) with primary refractory disease, and prognosis of pts reaching PFS24: Descriptive analysis of POLARIX.
Published in:
Hematological Oncology, 2023, v. 41, p. 432, doi. 10.1002/hon.3164_318
By:
- Herbaux, C.;
- Dietrich, S.;
- McMillan, A.;
- Thieblemont, C.;
- Gonzalez‐Barca, E.;
- Pinto, A.;
- Fogliatto, L.;
- Matasar, M.;
- Lee, C.;
- Hernandez, J.;
- Hirata, J.;
- Ho, R.;
- Launonen, A.;
- Boissard, F.
Publication type:
Article
AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS.
Published in:
Hematological Oncology, 2019, v. 37, p. 114, doi. 10.1002/hon.75_2629
By:
- Leonard, J.;
- Trneny, M.;
- Izutsu, K.;
- Fowler, N.;
- Hong, X.;
- Zhang, H.;
- Offner, F.;
- Scheliga, A.;
- Nowakowski, G.;
- Pinto, A.;
- Re, F.;
- Fogliatto, L.;
- Scheinberg, P.;
- Flinn, I.;
- Moreira, C.;
- Czuczman, M.;
- Kalambakas, S.;
- Fustier, P.;
- Wu, C.;
- Gribben, J.
Publication type:
Article
AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO.
Published in:
Hematological Oncology, 2019, v. 37, p. 227, doi. 10.1002/hon.42_2630
By:
- Gribben, J.;
- Trneny, M.;
- Izutsu, K.;
- Fowler, N.H.;
- Hong, X.;
- Zhang, H.;
- Offner, F.;
- Scheliga, A.;
- Nowakowski, G.;
- Pinto, A.;
- Re, F.;
- Fogliatto, L.;
- Scheinberg, P.;
- Flinn, I.;
- Moreira, C.;
- Czuczman, M.;
- Kalambakas, S.;
- Fustier, P.;
- Wu, C.;
- Leonard, J.
Publication type:
Article
POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO (AUGMENT).
Published in:
Hematological Oncology, 2019, v. 37, p. 226, doi. 10.1002/hon.41_2630
By:
- Thieblemont, C.;
- Leonard, J.;
- Trneny, M.;
- Izutsu, K.;
- Fowler, N.;
- Hong, X.;
- Zhang, H.;
- Offner, F.;
- Scheliga, A.;
- Nowakowski, G.;
- Pinto, A.;
- Re, F.;
- Fogliatto, L.;
- Scheinberg, P.;
- Flinn, I.;
- Moreira, C.;
- Czuczman, M.;
- Kalambakas, S.;
- Fustier, P.;
- Wu, C.
Publication type:
Article
A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT‐NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 554, doi. 10.1002/hon.2632
By:
- Wang, M.;
- Belada, D.;
- Cheah, C.;
- Chu, M.P.;
- Dreyling, M.;
- Flinn, I.;
- Fogliatto, L.;
- Goy, A.;
- Inwards, D.;
- Jurczak, W.;
- Mayer, J.;
- Re, F.;
- Robak, T.;
- Spurgeon, S.;
- Yoon, S.S.;
- Zinzani, P.L.;
- Yin, M.;
- Chen, T.;
- Kahl, B.
Publication type:
Article
AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS.
Published in:
Hematological Oncology, 2019, v. 37, p. 114, doi. 10.1002/hon.75_2629
By:
- Leonard, J.;
- Trneny, M.;
- Izutsu, K.;
- Fowler, N.;
- Hong, X.;
- Zhang, H.;
- Offner, F.;
- Scheliga, A.;
- Nowakowski, G.;
- Pinto, A.;
- Re, F.;
- Fogliatto, L.;
- Scheinberg, P.;
- Flinn, I.;
- Moreira, C.;
- Czuczman, M.;
- Kalambakas, S.;
- Fustier, P.;
- Wu, C.;
- Gribben, J.
Publication type:
Article
AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO.
Published in:
Hematological Oncology, 2019, v. 37, p. 227, doi. 10.1002/hon.42_2630
By:
- Gribben, J.;
- Trneny, M.;
- Izutsu, K.;
- Fowler, N.H.;
- Hong, X.;
- Zhang, H.;
- Offner, F.;
- Scheliga, A.;
- Nowakowski, G.;
- Pinto, A.;
- Re, F.;
- Fogliatto, L.;
- Scheinberg, P.;
- Flinn, I.;
- Moreira, C.;
- Czuczman, M.;
- Kalambakas, S.;
- Fustier, P.;
- Wu, C.;
- Leonard, J.
Publication type:
Article
POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO (AUGMENT).
Published in:
Hematological Oncology, 2019, v. 37, p. 226, doi. 10.1002/hon.41_2630
By:
- Thieblemont, C.;
- Leonard, J.;
- Trneny, M.;
- Izutsu, K.;
- Fowler, N.;
- Hong, X.;
- Zhang, H.;
- Offner, F.;
- Scheliga, A.;
- Nowakowski, G.;
- Pinto, A.;
- Re, F.;
- Fogliatto, L.;
- Scheinberg, P.;
- Flinn, I.;
- Moreira, C.;
- Czuczman, M.;
- Kalambakas, S.;
- Fustier, P.;
- Wu, C.
Publication type:
Article
A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT‐NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 554, doi. 10.1002/hon.2632
By:
- Wang, M.;
- Belada, D.;
- Cheah, C.;
- Chu, M.P.;
- Dreyling, M.;
- Flinn, I.;
- Fogliatto, L.;
- Goy, A.;
- Inwards, D.;
- Jurczak, W.;
- Mayer, J.;
- Re, F.;
- Robak, T.;
- Spurgeon, S.;
- Yoon, S.S.;
- Zinzani, P.L.;
- Yin, M.;
- Chen, T.;
- Kahl, B.
Publication type:
Article
Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial.
Published in:
Hematological Oncology, 2017, v. 35, p. 62, doi. 10.1002/hon.2437_49
By:
- Zinzani, P.;
- Thieblemont, C.;
- Melnichenko, V.;
- Osmanov, D.;
- Bouabdallah, K.;
- Walewski, J.;
- Majlis, A.;
- Fogliatto, L.;
- Caballero Barrigón, M.D.;
- Christian, B.;
- Gulbas, Z.;
- Özcan, M.;
- Salles, G.A.;
- Shipp, M.A.;
- Balakumaran, A.;
- Chlosta, S.;
- Chatterjee, A.;
- Armand, P.
Publication type:
Article

Found: 13

Patient socioeconomic status as a prognostic factor for allo-SCT.

Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase.

SUNMO: PHASE III TRIAL OF MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN IN RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMA.

Cause of death and prognosis of patients (pts) with primary refractory disease, and prognosis of pts reaching PFS24: Descriptive analysis of POLARIX.

AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R<sup>2</sup>) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS.

AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R<sup>2</sup>) THAN RITUXIMAB/PLACEBO.

POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R<sup>2</sup>) VS RITUXIMAB/PLACEBO (AUGMENT).

A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT‐NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA.

AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R<sup>2</sup>) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS.

AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R<sup>2</sup>) THAN RITUXIMAB/PLACEBO.

POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R<sup>2</sup>) VS RITUXIMAB/PLACEBO (AUGMENT).

A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT‐NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA.

Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial.